[go: up one dir, main page]

Schnee et al., 1987 - Google Patents

Construction and expression of a recombinant antibody-targeted plasminogen activator.

Schnee et al., 1987

View PDF
Document ID
13680727236827950317
Author
Schnee J
Runge M
Matsueda G
Hudson N
Seidman J
Haber E
Quertermous T
Publication year
Publication venue
Proceedings of the National Academy of Sciences

External Links

Snippet

Covalent linkage of tissue-type plasminogen activator (t-PA) to a monoclonal antibody specific for the fibrin beta chain (anti-fibrin 59D8) results in a thrombolytic agent that is more specific and more potent than t-PA alone. To provide a ready source of this hybrid molecule …
Continue reading at www.pnas.org (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • A61K47/48507—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site
    • A61K47/48515—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site not used; see subgroups
    • A61K47/48646—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site not used; see subgroups the antibody being targeting an enzyme

Similar Documents

Publication Publication Date Title
Schnee et al. Construction and expression of a recombinant antibody-targeted plasminogen activator.
CA1339445C (en) Recombinant hybrid immunoglobulin molecules and method of use
Suzuki et al. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation.
Reardan et al. Antibodies against metal chelates
Haber et al. Innovative approaches to plasminogen activator therapy
Nelles et al. Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158.
CA1341411C (en) Method for producing fv fragments in eukaryotic cells
US20030139365A1 (en) Expression and export of angiogenesis inhibitors as immunofusins
Runge et al. A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.
Laroche et al. Characterization of a recombinant single-chain molecule comprising the variable domains of a monoclonal antibody specific for human fibrin fragment D-dimer.
CA1339546C (en) Recombinant hybrid immunogloblin molecules an method of use
VANDAMME et al. Construction and characterization of a recombinant murine monoclonal antibody directed against human fibrin fragment‐D dimer
JPH05304992A (en) Hybridoma-monoclonal antibody and medicine containing antibody
Holvoet et al. Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase
WO1991016353A1 (en) Thrombus-specific antibody derivatives
Branscomb et al. Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator
EP0393045B1 (en) Fv antibody fragment production
Bulens et al. Construction and characterization of a functional chimeric murine–human antibody directed against human fibrin fragment‐D dimer
US5811265A (en) Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
Charpie et al. A bispecific antibody enhances the fibrinolytic potency of single-chain urokinase
EP0478366A2 (en) Recombinant hybrid immunoglobulin molecules and method of use
EP0347078A1 (en) Hybrid proteins
Kurokawa et al. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator
Bell et al. Chemical synthesis, cloning and expression in mammalian cells of a gene coding for human tissue-type plasminogen activator
CA2601271A1 (en) Targeted plasminogen activator fusion proteins as thrombolytic agents